Page 210 - 2020_01-Haematologica-web

V. Montefusco et al.
analysis of EMD patients at diagnosis, with the strength of using solid data derived from prospective trials. We con- firmed that PI are effective towards EMD, and, for the first time, we provide evidence that also lenalidomide is effec- tive in this difficult setting. We hope that our and other similar studies will draw attention to this unmet clinical
need with trials specifically designed for MM patients with EMD.
Acknowledgments
The authors thank Anna De Filippo for assistance in format- ting the paper.
References
1. Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. Soft-tis- sue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-3812.
2. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, pre- senting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010; 21(2):325-330.
3. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989- 5995.
4. Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myelo- ma prognosis is significantly worse in com- parison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360- 364.
5. Minnema MC, van de Donk NW, Zweegman S, et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant. 2008; 41(9):779-784.
6. Perez-Simon JA, Sureda A, Fernandez- Aviles F, et al. Reduced-intensity condition- ing allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia. 2006;20(3):542-545.
7. Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases. Cancer. 1969;23(1):167-174.
8. Thomas FB, Clausen KP, Greenberger NJ. Liver disease in multiple myeloma. Arch Intern Med. 1973;132(2):195-202.
9. Roccaro AM, Mishima Y, Sacco A, et al. CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal- Transition-like Transcriptional Activation. Cell Rep. 2015; 12(4):622-635.
10. Besse L, Sedlarikova L, Greslikova H, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016;97(1):93-100.
11. Bink K, Haralambieva E, Kremer M, et al. Primary extramedullary plasmacytoma: similarities with and differences from multi- ple myeloma revealed by interphase cytoge- netics. Haematologica. 2008;93(4):623-626.
12. Hillengass J, Moulopoulos LA, Delorme S, et al. Whole-body computed tomography versus conventional skeletal survey in
patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J. 2017;7(8):e599.
13. Cavo M, Terpos E, Nanni C, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017; 18(4):e206-e217.
14. Wu P, Davies FE, Boyd K, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230-235.
15. Durie BG. The role of anatomic and func- tional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42(11):1539-1543.
16. Landau H, Pandit-Taskar N, Hassoun H, et al. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treat- ment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary dis- ease. Leuk Lymphoma. 2012;53(2):275-281.
17. Masárová K, Stefanikova Z, Mistrik M, Batorova A. Effectiveness of lenalidomide and dexamethasone for the treatment of extramedullary plasmacytoma in patients with multiple myeloma: Report of two cases. Blood. 2014;124(21):5760.
18. Rosinol L, Cibeira MT, Blade J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832-836.
19. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
20. Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016; 127(8):971-976.
21. Gagelmann N, Eikema DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplan- tation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103(5):890-897.
22. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluo- rodeoxyglucose positron emission tomogra- phy-computed tomography, magnetic reso- nance imaging and whole-body planar radi- ographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50-55.
23. Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic reso- nance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before main- tenance therapy in symptomatic patients
with multiple myeloma included in the IFM/DFCI 2009 Trial: results of the IMA- JEM Study. J Clin Oncol. 2017; 35(25):2911- 2918.
24. Reed V, Shah J, Medeiros LJ, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117(19):4468-4474.
25. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125(20):3049-3058.
26. Rasche L, Angtuaco EJ, Alpe TL, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018;132(1):59-66
27. Jiménez R, Rosinol L, Cibeira MT, et al. Incidence and outcome of soft-tissue plas- macytomas in patients with multiple myeloma before and after the introduction of novel drugs. Blood. 2017;130(Suppl 1):3140.
28. Gay F, Magarotto V, Crippa C, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consoli- dation-maintenance for myeloma: updated results. Blood. 2013;122(8):1376-1383.
29. Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalido- mide followed by maintenance with borte- zomib-thalidomide compared with borte- zomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32(7):634-640.
30. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and mainte- nance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895-905.
31. Gay F, Oliva S, Petrucci MT, et al. Autologous transplant vs oral chemothera- py and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017;31(8):1727-1734.
32. Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102-1108.
33. Larocca A, Bringhen S, Petrucci MT, et al. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in eld- erly frail patients with untreated multiple myeloma. Leukemia. 2016;30(6):1320-1326.
34. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dex- amethasone in patients with newly diag- nosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63-69.
35. Bringhen S, D'Agostino M, De Paoli L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia. 2018;32(4):979-985.
200
haematologica | 2020; 105(1)